<SEC-DOCUMENT>0001628280-18-014296.txt : 20181113
<SEC-HEADER>0001628280-18-014296.hdr.sgml : 20181113
<ACCEPTANCE-DATETIME>20181113171220
ACCESSION NUMBER:		0001628280-18-014296
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181113
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181113
DATE AS OF CHANGE:		20181113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		181179042

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>q320188k-earningsrelease.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s04C24A3F4FC35E7BA63F096450FC0A6F"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;-sec-extract:summary;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">________________________________</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;">FORM 8-K</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">________________________________</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">PURSUANT TO SECTION 13 OR 15(D)</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.5546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:52%;"></td><td style="width:48%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of Report (Date of Earliest Event Reported):  November 13, 2018 (November 13, 2018)</font></div></td></tr></table></div></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">CUMBERLAND PHARMACEUTICALS INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:0%;"></td><td style="width:39%;"></td><td style="width:28%;"></td><td style="width:33%;"></td></tr><tr><td><font>&#160;</font></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tennessee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">001-33637</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">62-1765329</font></div></td></tr><tr><td><font>&#160;</font></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(State or other jurisdiction of incorporation)</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Commission File Number)</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(I.R.S. Employer Identification No.)</font></div></td></tr><tr><td><font>&#160;</font></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2525 West End Avenue, Suite 950, Nashville, Tennessee 37203</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Address of principal executive offices) (Zip Code)</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(615) 255-0068</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Registrant&#8217;s telephone number, including area code)</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Not Applicable</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Former name or former address, if changed since last report)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">____________________________________________&#160;</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#160;240.12b-2 of this chapter).</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2.02 &#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">On November 13, 2018, Cumberland Pharmaceuticals Inc. (the "Company") issued a press release which highlighted the operating results for the three and nine months ended September 30, 2018.  A copy of the press release is attached as </font><a style="text-decoration:underline;color:#0000FF;font-size:11pt;-sec-extract:exhibit;" href="q32018-ex991earningsrelease.htm"><font style="font-family:inherit;font-size:11pt;">Exhibit 99.1</font></a><font style="font-family:inherit;font-size:11pt;">&#32;to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02.</font></div><div style="line-height:120%;padding-top:15px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This information is furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, unless specifically incorporated by reference in a document filed under the Securities Act of 1933, as amended, or the Exchange Act. By filing this report on Form 8-K and furnishing this information, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by Item 2.02.</font></div><div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Statements and Exhibits</font></div><div style="line-height:174%;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)  Exhibits</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.5625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:20%;"></td><td style="width:13%;"></td><td style="width:67%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="q32018-ex991earningsrelease.htm"><font style="font-family:inherit;font-size:10pt;">99.1</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="q32018-ex991earningsrelease.htm"><font style="font-family:inherit;font-size:10pt;">Press release dated November 13, 2018</font></a></div></td></tr></table></div></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:24%;"></td><td style="width:13%;"></td><td style="width:12%;"></td><td style="width:13%;"></td><td style="width:12%;"></td><td style="width:13%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cumberland Pharmaceuticals Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated: November 13, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Michael Bonner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Michael Bonner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:15px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:384px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>q32018-ex991earningsrelease.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sF828B1788D375B5B9CDFBCFB5C5F9A26"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;"><img src="cumberlandpharmaimageaa05.jpg" alt="cumberlandpharmaimageaa05.jpg" style="height:92px;width:408px;"></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:174%;padding-top:4px;text-align:center;padding-left:96px;text-indent:120px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;CUMBERLAND PHARMACEUTICALS REPORTS                       </font></div><div style="line-height:174%;padding-top:4px;text-align:center;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;THIRD QUARTER 2018 FINANCIAL RESULTS</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NASHVILLE, TN (Tuesday, November 13, 2018) - Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)</font><font style="font-family:inherit;font-size:12pt;">, a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology supportive care today announced </font><font style="font-family:inherit;font-size:12pt;">third quarter</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">2018</font><font style="font-family:inherit;font-size:12pt;">&#32;financial results and Company update. Cumberland has a portfolio of eight U.S. Food and Drug Administration (FDA) approved brands. Net revenues for the quarter were </font><font style="font-family:inherit;font-size:12pt;">$8.5 million</font><font style="font-family:inherit;font-size:12pt;">. At the end of the third quarter, Cumberland had </font><font style="font-family:inherit;font-size:12pt;">$87 million</font><font style="font-family:inherit;font-size:12pt;">&#32;in total assets, including approximately </font><font style="font-family:inherit;font-size:12pt;">$48 million</font><font style="font-family:inherit;font-size:12pt;">&#32;in cash and marketable securities.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:20px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">RECENT HIGHLIGHTS:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Added to our commercial product line with the addition of </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Vibativ</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">, a patented, FDA approved, injectable product designed for the treatment of certain serious and difficult to treat infections</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Submitted an amendment to our FDA application for approval of our Next Generation </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Caldolor</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;product, containing additional requested quality and nonclinical data</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Filed a New Drug Application (NDA) to the FDA for the approval of our </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">RediTrex</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;methotrexate product line, designed for treating patients with arthritis and psoriasis</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Added to the growing library of literature supporting </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Caldolor</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt"> </sup></font><font style="font-family:inherit;font-size:12pt;">and </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Ethyol</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174; </sup></font><font style="font-family:inherit;font-size:12pt;">with a series of favorable clinical study publications</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Completed patient enrollment in the initial Phase II clinical study for </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Portaban</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;- the Company&#8217;s  product candidate for the treatment of Portal Hypertension</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Received $2 million grant awarded to </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Cumberland Emerging Technolgies (CET)</font><font style="font-family:inherit;font-size:12pt;">&#32;in support of a joint research program that addresses the significant need of improving clinical outcomes for certain lung cancer patients.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Our team has been very busy during the third quarter, working to maximize the potential of our existing brands while continuing to build a portfolio of differentiated products, " said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. &#8220;We continue to build a specialty pharmaceutical company that delivers sustained growth, profitable operations, and long-term value. Our strategy for achieving our goal is to establish a diversified portfolio of brands through a multi-faceted approach of both acquisition and internal development.&#8221;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:20px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">KEY DEVELOPMENTS:</font></div><div style="line-height:174%;padding-bottom:12px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Vibativ Acquisition</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">On November 6, 2018, the Company announced the acquisition of Vibativ</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(telavancin) from Theravance Biopharma. Vibativ is a patented, FDA approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Under the terms of the agreement, which closed on November 12, 2018, Cumberland assumed full responsibility for the product including its marketing, distribution, manufacturing, and regulatory activities. Cumberland will support Vibativ in the U.S. through its established hospital sales organization. The Company expects to selectively expand its sales force, medical science liaison and corporate teams to ensure the needed support of Vibativ as well as its oncology and acute care brands.</font></div><div style="line-height:174%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">RediTrex</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt"> </sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Approval Submission</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Also in November, the Company completed the submission and filed with the FDA an application for the approval of its methotrexate product line which is designed for treating patients with arthritis and psoriasis. This filing follows two meetings held with the FDA to discuss the approval pathway and requirements for the submission. We now await FDA&#8217;s determination of acceptance of the submission for their review.</font></div><div style="line-height:174%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Caldolor Submission</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In early 2018, the Company completed and filed the application for FDA approval of its Next Generation Caldolor product featuring an improved package and formulation. On August 2, 2018, Cumberland received a complete response from the FDA outlining the additional information needed for the application&#8217;s approval. The requests were for additional quality and nonclinical data.  The Company held a teleconference with the FDA during the third quarter to discuss their additional requirements. On September 26, 2018, Cumberland submitted an amendment to its application containing additional quality and nonclinical data and now awaits the FDA's response and approval decision.</font></div><div style="line-height:174%;padding-bottom:12px;padding-top:4px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">New Clinical Data Published</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In September 2018 the Company announced a new publication in </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Lung Cancer: Targets and Therapy</font><font style="font-family:inherit;font-size:12pt;">&#32;of a contemporary retrospective series showing that subcutaneous amifostine administered before radiotherapy postponed the onset of acute esophagitis in stage 3 small cell lung cancer patients. Cumberland markets branded amifostine in the U.S territory under the name Ethyol.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland also announced two favorable Caldolor study publications. A study at The Ohio State Wexner Medical Center, published in the </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Journal Frontiers in Surgery,</font><font style="font-family:inherit;font-size:12pt;">&#32;reveals more effective pain control and opioid-sparing activity with Caldolor when compared to ketorolac in patients undergoing arthroscopic knee surgery. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Additionaly, a clinical trial conducted at Tufts University School of Dental Medicine and published online in the </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Journal of Oral and Maxillofacial Surgery</font><font style="font-family:inherit;font-size:12pt;">, concluded that preemptive analgesia with Caldolor (IV ibuprofen) is more effective than IV acetaminophen in reducing both post-surgical pain and opioid use.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:174%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Ifetroban Phase II Studies</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">During the third quarter, we completed study enrollment for Portaban - the Company&#8217;s Portal Hypertension clinical program. Portaban is a form of ifetroban and is in development for the treatment of the portal hypertension associated with liver disease. This study was primarily designed to evaluate the safety of ifetroban treatment in this population and was not powered for any efficacy measurement.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">An initial review of the data from the study shows ifetroban was safe and well tolerated with no unexpected safety findings. We also measured hepatic venous pressure. Patients enrolled had a greater degree of variability than expected in their hepatic venous pressure gradient, therefore no definitive conclusions could be made on the impact of ifetroban on modulating that gradient. A full analysis of the data to include biomarkers and exploratory endpoints is ongoing. We will now await results from our other Phase II ifetroban studies before deciding on the best path for approval of our first new chemical entity.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland also continued to advance its Vasculan and Boxaban clinical pipeline programs, with patient enrollment progressing in each of those Phase II studies.</font></div><div style="line-height:174%;padding-bottom:12px;padding-top:4px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">New CET Small Business Grant Award</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">CET announced that the U.S. National Cancer Institute awarded $2 million in support of a joint research program involving Cumberland Pharmaceuticals, CET, and researchers at Vanderbilt University. This Phase II grant is awarded under the Small Business Innovation Research funding mechanism and follows successful completion of an initial Phase I award.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The objective of the collaborative research program is to further develop a novel small molecule radiosensitizing agent for the treatment of certain lung cancers. By enhancing the cancer&#8217;s sensitivity to radiation therapy, this technology addresses a significant medical need of improving clinical outcomes for these oncology patients.</font></div><div style="line-height:174%;padding-bottom:12px;padding-top:4px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">New Board Member</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">At Cumberland's Board meeting in September, the Company appointed Joseph C. Galante, American music industry executive, as its newest member of its Board of Directors. Mr. Galante is the former Chairman of Sony Music in Nashville and the Former President of RCA Records in New York City. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Mr. Galante joins as the Company's seventh "independent director" as defined under applicable SEC and NASDAQ rules and he serves on the Company's Audit and Compensation Committees. Mr. Galante's successful business track record, entrepreneurial and public company experience make him a valuable new member to Cumberland's Board of Directors.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:174%;padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">FINANCIAL RESULTS</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">: </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Net Revenue:  </font><font style="font-family:inherit;font-size:12pt;">For the nine months ended </font><font style="font-family:inherit;font-size:12pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:12pt;">, net revenues were </font><font style="font-family:inherit;font-size:12pt;">$27.2 million</font><font style="font-family:inherit;font-size:12pt;">&#32;compared to </font><font style="font-family:inherit;font-size:12pt;">$29.5 million</font><font style="font-family:inherit;font-size:12pt;">&#32;for the nine months ended </font><font style="font-family:inherit;font-size:12pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:12pt;">. The major driver of this decrease was the significant sales of Totect last year resulting from a competitive drug shortage.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">For the three months ended </font><font style="font-family:inherit;font-size:12pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:12pt;">, net revenues were </font><font style="font-family:inherit;font-size:12pt;">$8.5 million</font><font style="font-family:inherit;font-size:12pt;">, compared to </font><font style="font-family:inherit;font-size:12pt;">$11.2 million</font><font style="font-family:inherit;font-size:12pt;">&#32;for the prior year period.  </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Net revenue by product for the three months ended </font><font style="font-family:inherit;font-size:12pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:12pt;">, included </font><font style="font-family:inherit;font-size:12pt;">$3.0 million</font><font style="font-family:inherit;font-size:12pt;">&#32;for Kristalose</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;">$2.6 million</font><font style="font-family:inherit;font-size:12pt;">&#32;for Ethyol</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">. Net revenue for the Company&#8217;s other brands included </font><font style="font-family:inherit;font-size:12pt;">$1.3 million</font><font style="font-family:inherit;font-size:12pt;">&#32;for </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Caldolor</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;">$1.1 million</font><font style="font-family:inherit;font-size:12pt;">&#32;for Acetadote</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(including the brand and Company's Authorized Generic),  and </font><font style="font-family:inherit;font-size:12pt;">$0.3 million</font><font style="font-family:inherit;font-size:12pt;">&#32;for Omeclamox</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">-Pak.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:14pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Operating Expenses:</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Total operating expenses for the first nine months of </font><font style="font-family:inherit;font-size:12pt;">2018</font><font style="font-family:inherit;font-size:12pt;">&#32;were </font><font style="font-family:inherit;font-size:12pt;">$32.4 million</font><font style="font-family:inherit;font-size:12pt;">&#32;compared to </font><font style="font-family:inherit;font-size:12pt;">$32.7 million</font><font style="font-family:inherit;font-size:12pt;">&#32;for </font><font style="font-family:inherit;font-size:12pt;">2017</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:14pt;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Total operating expenses for the three months ended </font><font style="font-family:inherit;font-size:12pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:12pt;">&#32;were </font><font style="font-family:inherit;font-size:12pt;">$10.3 million</font><font style="font-family:inherit;font-size:12pt;">, compared to </font><font style="font-family:inherit;font-size:12pt;">$12.0 million</font><font style="font-family:inherit;font-size:12pt;">&#32;during the prior year period. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Earnings:</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Net income (loss) for the </font><font style="font-family:inherit;font-size:12pt;">third quarter</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">2018</font><font style="font-family:inherit;font-size:12pt;">&#32;was </font><font style="font-family:inherit;font-size:12pt;">$(1.6) million</font><font style="font-family:inherit;font-size:12pt;">&#32;or </font><font style="font-family:inherit;font-size:12pt;">$(0.11)</font><font style="font-family:inherit;font-size:12pt;">&#32;per diluted share, compared to </font><font style="font-family:inherit;font-size:12pt;">$(0.7) million</font><font style="font-family:inherit;font-size:12pt;">&#32;or </font><font style="font-family:inherit;font-size:12pt;">$(0.05)</font><font style="font-family:inherit;font-size:12pt;">&#32;a share for the prior year period. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Adjusted Earnings (loss) for the </font><font style="font-family:inherit;font-size:12pt;">third quarter</font><font style="font-family:inherit;font-size:12pt;">&#32;were </font><font style="font-family:inherit;font-size:12pt;">$(0.8) million</font><font style="font-family:inherit;font-size:12pt;">&#32;or </font><font style="font-family:inherit;font-size:12pt;">$(0.05)</font><font style="font-family:inherit;font-size:12pt;">&#32;per diluted share, compared to $</font><font style="font-family:inherit;font-size:12pt;">0.1 million</font><font style="font-family:inherit;font-size:12pt;">&#32;or </font><font style="font-family:inherit;font-size:12pt;">$0.01</font><font style="font-family:inherit;font-size:12pt;">&#32;per diluted share for the prior year period. The definition and reconciliation of Adjusted Earnings to net income is provided in this release.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Balance Sheet:</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;At </font><font style="font-family:inherit;font-size:12pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:12pt;">, Cumberland had </font><font style="font-family:inherit;font-size:12pt;">$47.8 million</font><font style="font-family:inherit;font-size:12pt;">&#32;in cash and marketable securities, including approximately </font><font style="font-family:inherit;font-size:12pt;">$38.3 million</font><font style="font-family:inherit;font-size:12pt;">&#32;in cash and equivalents. Total assets at </font><font style="font-family:inherit;font-size:12pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:12pt;">&#32;were </font><font style="font-family:inherit;font-size:12pt;">$87.4 million</font><font style="font-family:inherit;font-size:12pt;">.  Total liabilities were </font><font style="font-family:inherit;font-size:12pt;">$29.5 million</font><font style="font-family:inherit;font-size:12pt;">, including </font><font style="font-family:inherit;font-size:12pt;">$12.0 million</font><font style="font-family:inherit;font-size:12pt;">&#32;outstanding on the Company's revolving line of credit, resulting in Total shareholder's equity of </font><font style="font-family:inherit;font-size:12pt;">$58.2 million</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland also has approximately $44 million in tax net operating loss carryforwards, resulting from the prior exercise of stock options.</font></div><div><a name="s3E6D5F7B03CE50DF95E66F7DAD788CAF"></a></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Conference Call and Webcast</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A conference call and live Internet webcast will be held on Tuesday, November 13, 2018 at 4:30 p.m. Eastern Time to discuss the Company's </font><font style="font-family:inherit;font-size:12pt;">third quarter</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">2018</font><font style="font-family:inherit;font-size:12pt;">&#32;financial results. To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers).  A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 855-859-2056 (for U.S. callers) or 404-537-3406 (for international callers).  The Conference ID for the rebroadcast is 4258737. The live webcast and rebroadcast can be accessed via Cumberland's website at </font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">http://investor.shareholder.com/cpix/events.cfm</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">About Cumberland Pharmaceuticals</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the delivery of high-quality prescription brands to improve patient care. The Company develops, acquires, and commercializes brands for the hospital acute care, gastroenterology, and oncology market segments. These medical specialties are categorized by moderately concentrated prescriber bases that we believe can be penetrated effectively by small, targeted sales forces. </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:174%;padding-bottom:8px;padding-top:10px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Company&#8217;s portfolio of FDA approved brands includes:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Acetadote</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">acetylcysteine</font><font style="font-family:inherit;font-size:12pt;">) Injection, for the treatment of acetaminophen poisoning;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Caldolor</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">ibuprofen</font><font style="font-family:inherit;font-size:12pt;">) Injection, for the treatment of pain and fever;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Kristalose</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">lactulose</font><font style="font-family:inherit;font-size:12pt;">) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Omeclamox</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">-Pak</font><font style="font-family:inherit;font-size:12pt;">, (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">omeprazole, clarithromycin, amoxicillin</font><font style="font-family:inherit;font-size:12pt;">) for the treatment of Helicobacter pylori (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">H. pylori</font><font style="font-family:inherit;font-size:12pt;">) infection and related duodenal ulcer disease;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Vaprisol</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">conivaptan</font><font style="font-family:inherit;font-size:12pt;">) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Ethyol</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-style:italic;">&#32;(amifostine) </font><font style="font-family:inherit;font-size:12pt;">Injection, for the reduction of xerostomia (dry mouth) in patients undergoing post-operative radiation treatment for head and neck cancer and the renal toxicity associated with the administration of cisplatin in patients with advanced ovarian cancer; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Totect</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">(dexrazoxane hydrochloride) </font><font style="font-family:inherit;font-size:12pt;">Injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy in case of extravasation (drug leakage from the bloodstream into the tissues); and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:41px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:17px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Vibativ</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">telavancin</font><font style="font-family:inherit;font-size:12pt;">) Injection, for the treatment of certain serious bacterial infections</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland&#8217;s pipeline of product candidates includes:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Hepatoren</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">ifetroban</font><font style="font-family:inherit;font-size:12pt;">) Injection, a Phase II candidate for the treatment of critically ill patients suffering from liver and kidney failure associated with hepatorenal syndrome (&#8220;HRS&#8221;);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Boxaban</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">(ifetroban) </font><font style="font-family:inherit;font-size:12pt;">Oral Capsules, a Phase II candidate for the treatment of asthma patients with aspirin-exacerbated respiratory disease ("AERD");</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Vasculan</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">(ifetroban)</font><font style="font-family:inherit;font-size:12pt;">&#32;Oral Capsules, a Phase II candidate for the treatment of patients with the systemic sclerosis (SSc) form of autoimmune disease;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Portaban</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">(ifetroban) </font><font style="font-family:inherit;font-size:12pt;">Injection and Oral Capsules, a Phase II candidate for the treatment of patients with portal hypertension associated with liver disease; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">RediTrex</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">methotrexate</font><font style="font-family:inherit;font-size:12pt;">) Injection, an approval submission candidate for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:52px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">For more information on Cumberland&#8217;s approved products, including full prescribing information, please visit the individual product websites, links to which can be found on the Company&#8217;s website </font><font style="font-family:inherit;font-size:12pt;color:#0563c1;text-decoration:underline;">www.cumberlandpharma.com</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Acetadote</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;(acetylcysteine) Injection</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Acetadote, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, is indicated to prevent or lessen hepatic injury. Used in the emergency department, Acetadote is approved in the U.S. to treat overdose of acetaminophen, a common ingredient in many over-the-counter medications. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Acetadote is contraindicated in patients with hypersensitivity or previous anaphylactoid reactions to acetylcysteine or any components of the preparation. Serious anaphylactoid reactions, including death in a patient with asthma, have been reported in patients administered acetylcysteine intravenously. Acetadote should be used with caution in patients with asthma or where there is a history of bronchospasm. The total </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">volume administered should be adjusted for patients weighing less than 40 kg and for those requiring fluid restriction. To avoid fluid overload, the volume of diluent should be reduced as needed. If volume is not adjusted, fluid overload can occur, potentially resulting in hyponatremia, seizure and death. For full prescribing information, visit </font><font style="font-family:inherit;font-size:12pt;color:#0563c1;text-decoration:underline;">www.acetadote.com</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Caldolor</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;(ibuprofen) Injection</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Caldolor is indicated in adults and pediatric patients for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever.  It was the first FDA-approved intravenous therapy for fever.  Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with a history of asthma or other allergic type reactions after taking aspirin or other NSAIDs.  Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery.  Caldolor should be used with caution in patients with prior history of ulcer disease or GI bleeding, in patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart failure, liver impairment, and those taking diuretics or ACE inhibitors.  Blood pressure should be monitored during treatment with Caldolor.  For full prescribing information, including boxed warning, visit </font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">www.caldolor.com</font><font style="font-family:inherit;font-size:12pt;">&#32;.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Kristalose</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;(lactulose) Oral Solution</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Kristalose is indicated for the treatment of acute and chronic constipation. It is a unique, proprietary, crystalline form of lactulose, with no restrictions on length of therapy or patient age. Initial dosing may produce flatulence and intestinal cramps, which are usually transient. Excessive dosage can lead to diarrhea with potential complications such as loss of fluids, hypokalemia and hypernatremia. Nausea and vomiting have been reported. Use with caution in diabetics. Kristalose is contraindicated in patients who require a low-galactose diet. Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically. For full prescribing information, visit </font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">www.kristalose.com</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Omeclamox</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">-Pak (omeprazole, clarithromycin, amoxicillin)</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Omeprazole is an antisecretory drug, which works by decreasing the amount of acid the stomach produces. Clarithromycin and amoxicillin are antibacterial drugs, which inhibit the growth of bacteria allowing the stomach lining to heal. Omeclamox-Pak is contraindicated in patients with a history of hypersensitivity to omeprazole, any macrolide antibiotic or penicillin. The safety and effectiveness of Omeclamox-Pak in the pediatric population has not yet been established. Omeclamox-Pak was approved by the FDA in 2011. For full prescribing information, visit </font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">www.omeclamox.com</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Vaprisol</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;(conivaptan hydrochloride) Injection</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Vaprisol is an intravenous treatment for hyponatremia used in the critical care setting. Hyponatremia is an electrolyte disturbance in which sodium ion concentration in blood plasma is lower than normal.  This can be associated with a variety of critical care conditions including congestive heart failure, liver failure, kidney failure and pneumonia.  The product is a vasopressin receptor antagonist that raises serum sodium levels and promotes free water secretion. Vaprisol was approved by the FDA in 2005 for euvolemic hyponatremia and in 2007 for hypervolemic hyponatremia. For full prescribing information, visit </font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">www.vaprisol.com</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Ethyol</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;(amifostine) Injection</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Ethyol is indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer. It is indicated to reduce the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands. For more information please visit </font><font style="font-family:inherit;font-size:12pt;color:#00497f;text-decoration:underline;">www.ethyol.com</font><font style="font-family:inherit;font-size:12pt;color:#00497f;">.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Totect</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;(dexrazoxane) Injection</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Totect is an anthracycline extravasation agent approved by the FDA. Anthracyclines are used to treat many types of cancer and are among the most common cancer therapies. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Anthracycline extravasation occurs when there is accidental leaking of the intravenously-administered medication into the surrounding tissues.  Anthracycline extravasation can result in serious complications for cancer patients including tissue necrosis with skin ulceration. In addition to tissue damage, an anthracycline extravasation may cause damage to the nerves, tendons, muscle, and joints. For more information please visit </font><font style="font-family:inherit;font-size:12pt;color:#0563c1;text-decoration:underline;">www.totect.com.</font></div><div style="line-height:174%;padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Vibativ</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;(telavancin) Injection</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Vibativ is an FDA-approved antibiotic used in the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), as well as complicated skin and skin structure infections (cSSSI).  This lifesaving antibiotic is designed for difficult to treat Gram-positive bacterial infections, including those that are considered multidrug-resistant.  For more information please visit </font><font style="font-family:inherit;font-size:12pt;color:#0563c1;text-decoration:underline;">www.vibativ.com.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Cumberland Emerging Technologies (CET)</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland Emerging Technologies, Inc. (</font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">www.cet-fund.com</font><font style="font-family:inherit;font-size:12pt;">) is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, LaunchTN, and Gloria Pharmaceuticals. The mission of CET is to advance biomedical technologies and products conceived at Vanderbilt University and other regional research centers towards the marketplace. CET helps manage the development and commercialization process for select projects, and provides expertise on intellectual property, regulatory, manufacturing and marketing issues that are critical to successful new biomedical products. CET's Life Sciences Center, provides laboratory space, equipment and infrastructure for CET&#8217;s activities and other early-stage life sciences ventures.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Competition</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The pharmaceutical industry is characterized by intense competition and rapid innovation. Cumberland is devoted to providing advanced products that improve value of care for patients and address unmet or poorly met medical needs. We promote our approved products through our hospital and gastroenterology sales forces in the United States and are launching a network of relationships with international partners to bring our products to patients in their countries. Our continued success in developing and commercializing pharmaceutical products will depend, in part, upon our ability to compete against existing and future products in our target markets.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s60CD24D1423C59EBBA0CF559C54BF7DE"></a></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Forward-Looking Statements</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This release contains forward-looking statements within the meaning of the federal securities laws, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. These forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from them. Some important factors which may cause results to differ from expectations include: market conditions, competition, an inability of manufacturers to supply Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers including quality control obligation, maintaining an effective sales and marketing infrastructure, availability of additional debt and equity capital required to finance the business, market conditions at the time additional capital is required, our ability to continue to acquire brands, product sales, management of our growth and integration of our acquisitions, as well as other risks discussed in the &#8220;Risk Factors&#8221; section of the Company's most recent Annual Report on Form 10-K, and other filings with the SEC.  There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.6015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:3%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investor Contact:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Media Contact:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Erin Smith</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jeff Bradford</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate Relations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the Bradford Group</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(615) 255-0068</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(615) 515-4880</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">SOURCE: Cumberland Pharmaceuticals Inc.</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- MORE -</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sA36F7797CD7E5A3AB651E894EC37B6B0"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Balance Sheets</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,259,233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,412,868</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,533,703</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,672,476</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,055,138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,395,112</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,426,429</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,737,848</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,351,708</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,466,541</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,626,211</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,684,845</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">539,019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">528,882</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,370,330</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,444,545</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,809,306</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,486,830</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,432,076</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,232,312</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LIABILITIES AND EQUITY</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,447,429</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,979,929</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,070,860</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,714,814</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,518,289</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,694,743</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revolving line of credit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,000,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,800,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,969,174</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,815,968</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,487,463</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,310,711</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commitments and contingencies</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders&#8217; equity:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Common stock&#8212;no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,235,612</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,410,941</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Retained earnings</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,966,252</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,709,222</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:92px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total shareholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,201,864</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,120,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(257,251</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(198,562</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:68px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,944,613</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,921,601</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:68px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities and equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,432,076</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,232,312</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sF4A31256BFEC5BB89C7F051E8D4E704F"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Statements of Operations and Comprehensive Income (loss)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,492,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,196,961</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,243,859</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,500,843</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Costs and expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of products sold</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,460,463</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,166,353</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,511,743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,216,776</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling and marketing</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,803,112</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,226,438</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,549,873</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,174,391</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,306,055</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">943,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,631,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,921,951</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,067,981</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,090,785</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,732,485</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,554,158</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">661,802</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">609,572</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,946,457</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,811,589</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total costs and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,299,413</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,036,310</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,371,942</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,678,865</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,806,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(839,349</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,128,083</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,178,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,220</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,833</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">398,420</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">216,849</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,199</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,902</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(59,520</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(70,646</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,659,862</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(753,418</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,789,183</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,031,819</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax (expense) benefit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,159</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,822</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,477</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,196,192</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,664,021</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(757,240</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,801,660</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,228,011</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss at subsidiary attributable to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,977</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,209</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,689</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,923</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) attributable to common shareholders</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,643,044</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(743,031</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,742,971</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,178,088</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Earnings (loss) per share attributable to common shareholders</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">- basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.05</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.30</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.45</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">- diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares outstanding</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">- basic</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,573,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,867,159</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,645,230</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,973,737</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">- diluted</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,573,108</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,867,159</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,645,230</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,973,737</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive income (loss) attributable to common shareholders</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,643,044</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(743,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,742,971</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,178,088</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss at subsidiary attributable to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,977</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,209</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,689</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,923</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Comprehensive income (loss)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,664,021</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(757,240</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,801,660</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,228,011</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s9CF18E17D53A5AD1AE11117CF53D4891"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Statements of Cash Flows</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:66%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,801,660</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,228,011</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,108,051</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,974,194</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,293,963</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,005,239</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">849,198</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Excess tax (benefit) expense derived from exercise of stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(91,109</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Noncash interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,117</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,708</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Noncash investment gains</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(131,652</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,084</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net changes in assets and liabilities affecting operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,339,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,748</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311,419</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(485,739</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">966,817</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(428,176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,595,243</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">640,453</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,486</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">239,703</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by (used in) operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(610,452</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(98,152</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions to property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(171,731</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(172,899</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,851,951</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,029,414</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from sale of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,122,376</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,644,592</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions to intangibles</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,411,710</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(841,647</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in investment activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,313,016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,600,632</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Borrowings on line of credit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,000,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,700,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Repayments on line of credit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,800,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,800,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales of shares of common stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,909</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments of deferred offering costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(248,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments made in connection with repurchase of common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,382,968</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,893,857</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(230,167</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,006,143</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net (decrease) increase in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,153,635</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,508,623</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,412,868</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,510,330</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,259,233</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,018,953</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sC2611732A7985B1C82BB29F03182D423"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Reconciliation of Net Income (loss) Attributable to Common Shareholders to Adjusted Earnings and Adjusted Diluted Earnings Per Share</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three months ended September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three months ended September 30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Earnings impact</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Earnings per share impact</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Earnings impact</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Earnings per share impact</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net income (loss) attributable to common shareholders</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,643,044</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(743,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Net loss at subsidiary attributable to noncontrolling interests</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,977</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,209</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,664,021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(757,240</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustments to net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,159</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,822</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">713,323</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">659,901</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation (a)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">339,930</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">297,943</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(166,220</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94,833</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,902</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Adjusted Earnings (loss) and Adjusted Diluted Earnings (loss) Per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(753,630</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.05</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,495</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.01</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted weighted-average common shares outstanding:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,573,108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,280,883</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Represents the share-based compensation of Cumberland.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Company provided the above adjusted supplemental financial performance measures, which are considered "non-GAAP" financial measures under applicable SEC rules and regulations. These financial measures should be considered supplemental to, and not as a substitute for, financial information prepared in accordance with Generally Accepted Accounting Principles ("GAAP"). The definition of these supplemental measures may differ from similarly titled measures used by others.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Because these supplemental financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the supplemental financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland's management believes these supplemental financial performance measures are important as they are used by management, along with financial measures in accordance with GAAP, to evaluate the Company's operating performance.  In addition, Cumberland believes that they will be used by certain investors to measure the Company's operating results. Management believes that presenting these supplemental measures provides useful information about the Company's underlying performance across reporting periods on a consistent basis by excluding items that Cumberland does not believe are indicative of its core business performance or reflect long-term strategic activities.  Certain of these items are not settled through cash payments and include: depreciation, amortization, share-based compensation expense and income taxes.  Cumberland utilizes its net operating loss carryforwards to pay minimal income taxes.  In addition, the use of these financial measures provides greater transparency to investors of supplemental information used by management in its financial and operational decision-making, including the evaluation of the Company's operating performance.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Company defines these supplemental financial measures as follows:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Adjusted Earnings (loss): </font><font style="font-family:inherit;font-size:12pt;">net income (loss) adjusted for the impact of income taxes, depreciation and amortization expense, share-based compensation and interest income and interest expense.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Adjusted Diluted Earnings (loss) Per Share:</font><font style="font-family:inherit;font-size:12pt;">&#32;Adjusted Earnings (loss) divided by diluted weighted-average common shares outstanding. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>cumberlandpharmaimageaa05.jpg
<TEXT>
begin 644 cumberlandpharmaimageaa05.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" #3 Z # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD+W5_J%T\\\S8ZM(Y+,?J:^CRWA2=:HI8F24>J6K?EY?(\[&8[V5-N!]M_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M (N_$74?$)D!9]*A'V+2U_V1:Q-F1?:=Y>]<]\.3^[C4# "@!1T Q7I.L_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $9E1=S' '>O'_VQ
M_P!K[P'^R1\-F\6Z^POM7O\ =;^'/#\4NV74;D#.,X.R-00SR$85?5BJGT#X
MJ_$KP9\(?AUK7Q,\?ZU%8:1H5A)>:A<R'[L:#. .K,> JCEB0!R17X@_'?\
M:<\9_M<?&^_^,/B^22&&4_9]"TDR933+%6.R$8XW'[\C?Q.QYVA0/9RC*Y9A
M4<Y:0COY^1S5ZWL].IZ-J7Q1\??&_P"(5U\4OBCKIU'6;[Y-ZJ4AM8 Q*V\"
M9/EQ+Z=6.68LQS7K?P[^Y%]17@OP\!;R\#/3I7MG@CQ-H>GWD.D2WRRWSX,6
MFVL;SW4O^Y!$#(__  %37TN,IPIQ2222V78RIW>Y]&_#G[D?T%>DZS_R /\
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MCSZ^:9?A:GLZM1*78_86BOQW'_!W?\*/^C*O$'_A80?_ "/1_P 1=_PHZ?\
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M^W5I_P 4VM? ?Q:6#3?$3A8[2_BPEKJ3=, '_52G^X20W\)_A'TDC;U#8Q0
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MA2O]P_2DAYCZ=S_.E?[A^E?E4%96/OWL?QV?M9_\G4_$S_LH.L_^ETU?H_\
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M3YI=HV0ZCX!>-2?0O'>N1^"FOW HKXR/%F?Q=_;?A'_(^H?#N3O_ )=?B_\
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MU3#8I>_#X?/R^6_H><_%CQY^T;_P5\_;Z?4],TV2^\3^/]<2QT#2O-8PZ79
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MGX1\%_M4_$?2-*TZ!8;#2]+\;W]O;VT0Z)'''*%11V  %5/VL_\ DZCXF?\
M90-9_P#2Z:OZ3?\ @D9\ /@1XE_X)K_!?7/$?P6\)W][=> K*2YN[WP[;2RS
M.5Y9F9"6/N:_9,VS6CE.74:E6GSJ22MIVWU/S#+,NK9CC*D:=3D:UZZZ^31_
M.9_PWI^W-_T>9\5?_#@ZE_\ 'JTO!O[=O[<5SXNTJVG_ &Q_BFZ2:E K(_Q!
MU$A@9%&#F:OZL/\ AF/]FW_HWWP3_P"$K:?_ !NA?V9?V<$8/'\ /!2LI!5E
M\+6@(/J"(^*^;EQC@'%KZHOO7^1] N&<6I:XA_C_ )G5^'G:31X'8DDQ*<D]
M?E%7:;##%;QB*% JCH!3J^ ;N[GV 5XQ_P %'O\ E'G\=_\ LC?B?_TU7->S
MUXQ_P4>_Y1Y_'?\ [(WXG_\ 35<UOA?]ZI_XE^9AB?\ =I^C_(_D8TZ[%A?V
M]\4W>3,LFW.,X;./TK]HK3_@[CL;2V2W/[%5RQ50-W_";JO08_Y]3Z5^+^E6
ML5]J=M93DA)IU1RO4 M@XK]X;+_@TQ_9*N[1)V_:9^(H+*"0(+' R <?ZBOU
MKB&>0QC2_M%-O7EM?Y[/T/SG(XYQ*,W@6DKJ][>=M_F<'_Q%VV/_ $9-<_\
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MOSS6VI]B_A/Y$_\ @HM_R?[\:O\ LJFO?^E\U?T4?\$ /^40_P '/^O#5?\
MT\7U?SK_ /!1;_D_WXU?]E4U[_TOFK^BC_@@!_RB'^#G_7AJO_IXOJ_2^+?^
M1%A_6/\ Z2?#</?\CFO_ -O?^E(^QJ***_-3[H**** "@G%%8_COQEH/P_\
M"NH>-/%.K16.F:58S7>H7D[ )##&A=W8GL ":+-M)=T%TM6?F[_P<L?M\']G
MK]E./]EWP/K?E>*?BAO@O3%*?,L]&C;_ $A_5?-;$ ]5,WI7Y\_\&WW["#?M
M2_MF)\=O&6D>=X3^%9CU,B:/]W<ZNQ8V<0/<QLIG/IY2#^*OF3_@I/\ MG>(
M?V]/VPO%O[06IW$XTNZO39^%;&7C['I4)*VZ8' 9E_>/ZO(YKZ<_X)L_\%Z]
M._X)O_LX6OP%\#?LA6&LW#ZE<:AKGB"X\5-!+J-U(<!V06[;0L:QQJ,GA,]2
M:_5:>4XW+N&_JV&A>K4^+RO_ )+3\3\\GF6%Q6>>UQ$OW<-OEMM?KJ?T=PQ"
M.'RR@QSQ7YS?\')'[!G_  U#^R"GQW\"Z&LOB_X5B;45,,7[R[TEP/M</'+%
M-J3*.WEOC[QKY@_XB\/&/_1DVE_^%K)_\BU7U/\ X.V_$.LV,VF:I^PWI%Q;
MW$313PR^,Y"LB,,,I'V7D$'&*^9P'#_$6 QD,13I:Q=]UKW6_8][&9WD>,P\
MJ,ZNDO*7^1\8?\$2OV^;G]@_]M71M?\ $NKR0^"?%X31?&,;.?+BAD<>3=D>
ML,I5B>NQI /O5_499WUM>0Q2V\RR+)$'1T;(8$9!![U_&7\0-<\-^(_'>L^(
M?!?A;^PM*O\ 5)KC3-&%R9OL$#R%D@$A WA 0H) )VYK^B__ (-V?^"@,?[7
M/['UO\)?'6N^?XV^&$<>E:CYSYDO-/QBSN?4X1?)8\G=#D_?%>OQKECG".80
M793_ $?Z/Y'G\+Y@H.6#D]-7']5^OWGZ&44B,'7<K9![BEK\YZ'VCV/Y@O\
M@X9_Y2S?$O\ ZY:5_P"FZWK]F?\ @W/C1_\ @D7\,-Z XN=>ZC_J-WU?C+_P
M<,_\I9OB7_UQTK_TW6]?LY_P;F_\HBOAC_U\Z[_Z>[ZOT/B&_P#JIA/^W?\
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MTKP'QY^Q_P"-OAB\FM>!+F;Q)I2_,]L8P+^!?]U %G '9 K^BL>:^LJ",C%
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MEF%]@J#EK>^JW^3/ZS/^&C/V>^G_  O;P;_X5%I_\<I)/VC?V?51F'QU\&Y
M)Q_PD]I_\<K^33_AA+]MG_HT?XD?^$7??_&J/^&$OVV>W[(_Q(_\(N^_^-5Y
M*X,P+?\ O:^Y?_)'H_ZS8[_H&?WO_(_57_@Z9_;,^!/Q+^$G@']F_P"&7Q2T
M3Q#KEIXKEUK6(-"U**Z6QACMI(8Q*T;$([F9L*3G"$D 8S\F_P#!M5:74_\
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M2>!6=7@_!4Z4I+%IV3>R_P#DC2EQ)C:E6,7AFKM+K_D?U8@Y/\J\9_X*/?\
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MQ)UJXL;VT\(WDL4\3WLK(Z.L9#*0001U%>2_\,*_MM;=O_#(_P 2/_"+OO\
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MYT6[V>_ET9]AAZRQ-"-2UN9?CV/Y@O\ @X9_Y2S?$O\ ZXZ5_P"FZWK]G/\
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M1E Z!P#B0>S BO0_!O\ P5:^./@-%L_B#X;TKQ3;H &E_P"/.Y(]2Z*T9/\
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MCN)L3.=HHV+G(4?E2T4;B=Q-HZD"D,:\X49/?%.HH!:"*BIT4#Z"EHHHLEL
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M=5O4BFU24.B&.!3S(VZ6,8'=U]:] C8L@8CK7Y/_ /!>[_E(K^Q%_P!C_/\
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M>R7=O9'Z$_ O]H[X'?M)^%Y_&WP)^+&@^+=(M[LVLNH:%J"3QQSJ 6C8J>&
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M=*\3Z!<RR10:OHUTL\$DD;%74.O!(((/H:ZVO@+_ (-H?^44WA;_ +&;6?\
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MPDZR5VD?JO:S-.I<].V1BDU"[CL;1[R:542-2TCMT4 9)HLO]6?]XU0\<?\
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M^Q5B*^DCF$<)A,%46J2FI+NF]5\T>%]4EB:^*B]+\K3\TM']Y\1?M\_\%=/
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M:OC?XQ0R_P#!+?XI>-[;QSXU?4+&\TVV-LB1QR3A3\T;[PPE!!&.GO7U>/\
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M]RBO#Q=#ZKBIT;WL]UJFNC5CU\/6^L48U+6;Z/IW0DG^K;_=-?DS_P %H?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+%%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
